Respiratory Biologics Have Significantly Reduced Asthma Exacerbations
A large-scale study finds that the introduction of asthma biologics in 2015 has led to immediate and sustained reductions in exacerbations at the population level.
A large-scale study finds that the introduction of asthma biologics in 2015 has led to immediate and sustained reductions in exacerbations at the population level.
Rextovy, a 4 mg naloxone medication, will be available for purchase without a prescription at retail stores and online.
Read MoreENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.
Read MoreResearchers discovered manikomycin, a soil-derived peptide that attacks bacteria in a unique way to bypass existing antibiotic resistance.
Read MoreReal-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
Read MoreResearchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read MoreResearchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
Read MoreCombining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read MoreResearchers at Adelaide University developed a lipid-polymer vehicle that improves drug bioavailability and reduces systemic toxicity in preclinical models of lung cancer.
Read MoreFor every 100 children vaccinated against influenza, between nine and 14 cases are prevented, according to Harvard Medical School data.
Read MoreUpdated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.
Read MoreResearchers developed an avian flu vaccine platform that generates immunity in the respiratory tract and bloodstream to combat H5N1.
Read MoreA study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
Read MoreBenralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read MoreEnanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read MoreData from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read MorePhase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
Read More